CRISPR THERAPEUTICS AG
NASDAQ: CRSP (CRISPR Therapeutics AG)
Last update: 5 hours ago40.15
-0.22 (-0.54%)
| Previous Close | 40.37 |
| Volume | 4,108,033 |
| Price / Sales | 174.15 |
| Price / Book | 2.48 |
| 52 Weeks Range |
| Operating Margin (TTM) | -17,158.84% |
| Diluted EPS (TTM) | -4.49 |
| Quarterly Revenue Growth (YOY) | 71.60% |
| Total Debt/Equity (MRQ) | 11.99% |
| Current Ratio (MRQ) | 15.64 |
| Operating Cash Flow (TTM) | -306.47 M |
| Levered Free Cash Flow (TTM) | -193.24 M |
| Return on Assets (TTM) | -12.88% |
| Return on Equity (TTM) | -19.71% |
News Mood
- CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results
- CRISPR Therapeutics Eyes Late-Stage Trials as Key Data and CASGEVY Demand Build
AIStockmoo Score
| Value 30% | -0.9 |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Low debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info | |
| Earns below its cost of capital. Returns on capital rising. info | |
| Timing 30% | -1.7 |
| From our AI technical analysis of the chart. info | NA |
| No clear trend over the past year. Far below its 52-week high. info | |
| Candle Patterns info | NA |
| Trend for Your Holding Period info | NA |
| Sentiment 20% | 0.4 |
| No recent price targets, so based on how targets have been revised. info | |
| Recent news mostly positive. info | |
| Smart Money 20% | 0.6 |
| Insider Activity info | NA |
| Institutions net +0.42% of shares in their latest 13F filings: 251 holders increased, 209 decreased (quarter to 30 Sep 2026). info | |
| Short interest -8.4% from 31 Aug to 30 Oct 2026, 13.1 days to cover (FINRA). info | |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector lagging the market. | |
| The pillars agree, so the score is strengthened. | |
| Not in score | |
| Price is low against its 52-week average. Down over 5 years. info | |
| Trend down on all three terms. Short-term momentum falling. info | |
| Levels trending down. info | |
| Final Score | -0.66 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | CRISPR Therapeutics AG | Mixed | Bearish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| CRSP | - | - | - | 2.48 |
| GMAB | - | - | - | 4.99 |
| REGN | - | 0.39% | - | 2.95 |
| ABVX | - | - | - | 16.72 |
| FOLD | 5 B | - | - | - |
| IGMS | 71 M | - | - | 0.760 |
Select this tab to load the latest available analysis.
|
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Value |
| % Held by Insiders | 1.69% |
| % Held by Institutions | 76.46% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ark Investment Management Llc | 30 Sep 2026 | 10,056,844 |
| Orbis Allan Gray Ltd | 30 Sep 2026 | 4,519,261 |
| Gsk Plc | 30 Sep 2026 | 2,608,419 |
| Sumitomo Mitsui Trust Group, Inc. | 30 Sep 2026 | 1,453,713 |
| Amova Asset Management Americas, Inc. | 30 Sep 2026 | 1,453,513 |
No data within this time range.
Institutions
Institutional ownership: 81.86%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 251 | 6,196,285 |
| Decreased | 209 | 6,222,834 |
| New | 65 | 826,959 |
| Sold out | 67 | 394,972 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
Short Interest
| Settlement | Shares | Days to cover |
|---|---|---|
| 30 Oct 2026 | 17,189,067 | 13.1 |
| 15 Oct 2026 | 16,442,415 | 10.2 |
| 30 Sep 2026 | 18,679,198 | 9.6 |
| 15 Sep 2026 | 19,071,093 | 16.5 |
| 31 Aug 2026 | 18,769,995 | 10.7 |
| 14 Aug 2026 | 18,744,855 | 15.6 |
FINRA short interest via Nasdaq, reported twice a month.
| Date | Type | Details |
|---|---|---|
| 17 Nov 2026 | Yahoo Finance |
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store. |
| 17 Nov 2026 | Yahoo Finance |
CRISPR Therapeutics Eyes Late-Stage Trials as Key Data and CASGEVY Demand Build
CRISPR Therapeutics (NASDAQ:CRSP) is preparing to advance several experimental treatments toward late-stage trials, with executives pointing to upcoming data from its cardiovascular and cell therapy programs and growing demand for its commercial product, CASGEVY. CEO Sam Kulkarni said during a Jeff… |
| 10 Nov 2026 | Yahoo Finance |
CRISPR Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
ZUG, Switzerland and BOSTON, Nov. 10, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Tuesday, November 17, 2026 at 10:00 a.m. GMT. A live… |
| 09 Nov 2026 | Yahoo Finance |
CRISPR Therapeutics Presents Phase 1b Data for CTX310® Demonstrating Reductions in ANGPTL3 and Triglycerides in Patients with Severe Hypertriglyceridemia at the American Heart Association (AHA) Scientific Sessions 2026
-Data presented in a late-breaking oral presentation at AHA- -A single-course treatment with CTX310 produced a mean reduction from baseline of 65% in circulating ANGPTL3 and 63% in triglycerides (TG) at Day 30 in patients with severe hypertriglyceridemia (sHTG), who had a median baseline TG level… |
| 08 Nov 2026 | Yahoo Finance |
CRISPR Therapeutics Provides Update on Zugocabtagene Geleucel (Zugo-cel) in Refractory Rheumatologic Autoimmune Diseases
Systemic sclerosis (SSc) data presented at ACR Convergence 2026 showed 83% (5/6) of patients receiving standard lymphodepletion achieved a clinical response (rCRISS-25) at Month 3, with all responders maintaining response Zugo-cel has been well tolerated in all 21 patients dosed to date, with no… |
| 06 Nov 2026 | Yahoo Finance |
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. |
| 04 Nov 2026 | Yahoo Finance |
CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition
ZUG, Switzerland and BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data in patients with relapsed or refractory large B-cell lymphoma from the ongoing Phase 1/2 trial of zugocabtagene geleucel (zugo-cel), its investigational allogeneic… |
| 03 Nov 2026 | Yahoo Finance |
Vertex Slumps On Light Pain Drug Sales, But A Key Kidney Catalyst Lies Ahead
Vertex stock slumped Tuesday despite notching a definitive beat for its Crispr-partnered blood diseases gene editor, Casgevy. |
| 03 Nov 2026 | Yahoo Finance |
Why Did CRISPR Therapeutics (CRSP) Stock Slide After Its Latest Update?
CRISPR Therapeutics (CRSP) has released its third quarter 2026 results, reporting revenue of US$12.67 million and a net loss of US$111.44 million, providing investors with updated financial data to review. The latest quarterly update and pipeline news landed against a backdrop where CRISPR… |
| 03 Nov 2026 | Yahoo Finance |
CRISPR Therapeutics (CRSP) Stock Looks Fully Valued As It Names A New CTO
CRISPR Therapeutics has been a volatile ride for shareholders, and the latest moves raise a straightforward question for anyone looking at the stock today. Is the current share price meaningfully supported by what sits on its balance sheet in terms of book value, or is the market asking you to pay… |
| 03 Nov 2026 | Yahoo Finance |
CRISPR Therapeutics (CRSP) Appoints Siva Sakhamuri As Chief Technical Officer
CRISPR Therapeutics (NasdaqGM:CRSP) appointed Siva Sakhamuri, Ph.D., as Chief Technical Officer, according to a recent company announcement. Dr. Sakhamuri brings experience leading technical operations and manufacturing functions at established biotechnology enterprises focused on complex… |
| 03 Nov 2026 | Yahoo Finance |
Crispr Therapeutics Reports Growing Casgevy Use Ahead of Key Pipeline Data, RBC Says
Crispr Therapeutics (CRSP) is seeing continued growth in the use of its gene-editing treatment Casge… |
| 03 Nov 2026 | Yahoo Finance |
CRSP's Q3 Loss Wider Than Expected, Sales Beat Estimates
CRISPR Therapeutics reports higher-than-expected Q3 sales as Casgevy sales surge, while expanding pediatric approvals and advancing multiple clinical programs. |
| 03 Nov 2026 | Yahoo Finance |
VRTX's Q3 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised
Vertex misses Q3 earnings estimates but beats revenue expectations, driven by CF drug sales and growth in Casgevy and Journavx, prompting a 2026 sales outlook hike. |
| 02 Nov 2026 | Yahoo Finance |
CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Tops Revenue Estimates
CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of -8.49% and +27.39%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 02 Nov 2026 | Yahoo Finance |
Casgevy Starts Paying Off for CRISPR: Rapid Earnings Reaction
CRISPR's first approved therapy is gaining traction, but the company's finances still lean on its cash reserves and an expensive pipeline. |
| 02 Nov 2026 | Yahoo Finance |
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results
– CASGEVY® revenue of $99 million in the third quarter of 2026, up 30% quarter-over-quarter and nearly six times the third quarter of 2025 – – CASGEVY approved in the U.K. for children 5 years of age and older with severe SCD or TDT, and in the United Arab Emirates and Bahrain for children 2 years… |
| 02 Nov 2026 | Yahoo Finance |
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
| 02 Nov 2026 | Yahoo Finance |
CRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical Officer
ZUG, Switzerland and BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced the appointment of Sivakesava (Siva) Sakhamuri, Ph.D., as Chief Technical Officer, effective immediately. Dr. Sakhamuri brings about 30 years of technical operations and manufacturing… |
| 30 Oct 2026 | Yahoo Finance |
Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $51.36, moving 5.34% from the previous trading session. |
| Show more | ||
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |